3 assets in Infiltrating Bladder Lymphoepithelioma-Like Carcinoma

Therapeutic assets addressing Infiltrating Bladder Lymphoepithelioma-Like Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Infiltrating Bladder Lymphoepithelioma-Like Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Infiltrating Bladder Lymphoepithelioma-Like Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Infiltrating Bladder Lymphoepithelioma-Like Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)